Current management of digitalis intoxication
Southern Medical Journal
|August 1, 1976
Summary
Digitalis toxicity significantly increases mortality in hospitalized patients. Avoiding digitalis in high-risk situations and recognizing/treating toxicity are crucial for successful patient outcomes.
Area of Science:
- Pharmacology
- Clinical Medicine
- Cardiology
Background:
- Digitalis is a commonly prescribed medication with a narrow therapeutic index.
- A significant percentage of patients admitted to hospitals are already experiencing digitalis toxicity.
- Digitalis toxicity is associated with increased mortality rates.
Purpose of the Study:
- To highlight the risks associated with digitalis therapy.
- To emphasize the importance of recognizing and managing digitalis toxicity.
- To outline strategies for the safe and effective use of digitalis.
Main Methods:
- Review of existing literature on digitalis pharmacology and clinical use.
- Analysis of patient data regarding digitalis toxicity and outcomes.
- Identification of key indicators for digitalis intoxication.
Main Results:
- Digitalis exhibits one of the highest therapeutic-toxic ratios among commonly used drugs.
- 20% to 30% of hospitalized patients on digitalis are in a toxic state upon admission.
- Failure to manage toxicity leads to significantly increased mortality.
Conclusions:
- Successful digitalis use hinges on preventing toxicity through careful patient selection.
- Prompt recognition of digitalis intoxication signs, symptoms, and ECG findings is essential.
- Complete cessation of digitalis is the primary treatment for digitalis intoxication.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...